Skip to content
Saturday, November 14, 2026
TechSphere Blog

Administering Pluripotent Cells During Pregnancy to Infants with Spina Bifida Boosts Life Outcomes, Trial Finds

A pioneering research effort has discovered that administering stem cells to unborn babies affected by spina bifida while undergoing fetal surgery could constitute a "important advancement" in treating birth defects.

Study Parameters and Security

The US-based trial involved six unborn babies with the 'open' form of spina bifida. Doctors administered regenerative cells sourced from the maternal placenta directly onto the baby's spinal cord as part of the surgical correction.

Significantly, the regenerative treatment demonstrated a favorable safety profile. Researchers confirmed that the cells did not cause cancerous growths, hinder surgical recovery, or prevent the reversal of associated brain abnormalities.

Promising Outcomes

Imaging conducted after delivery showed a successful correction of Chiari malformation in each of the babies. This neurological improvement is a key indicator for better mobility and function.

"In the event it allows more children capable of walking who previously could not, then it would become the conventional approach," said the lead researcher. "These findings are profoundly encouraging and pave the way for lots of potential novel therapies."

Broader Impact and Encouragement

Experts not involved in the trial indicated that subsequent studies of these apparent benefits could herald a "different age" in fetal surgery. The potential to improve neural deficits occurring during fetal development is regarded as a revolutionary objective.

Notably important would be advancements for urogenital and gastrointestinal outcomes, which are common challenges for people affected by this disorder.

The Path Forward

Despite this being a first-in-human effort focused on a handful of cases, its safety demonstration and positive signals offer a robust platform for broader investigative efforts. The integration of stem cell therapy with current in-utero repair procedures holds considerable promise for transforming outcomes for future generations with this neural tube defect.

About the author

James Garrison

A tech enthusiast and software developer with over a decade of experience in AI and web technologies, passionate about sharing knowledge.

TechSphere Blog

Type to search articles.